drugset / Trial / NCT00755118
Lohp, 5-Fu/Lv and Bevacizumab, Alternative With Cpt-11, 5-Fu/Lv and Cetuximab In Metastatic Crc
NaSingle-groupOpen-labelTreatment
Summary
The aim of this study is to evaluate the efficacy of the effective drugs in a alternating chemotherapy schedules in pretreated patients with mCRC, who have received all effective drugs.
Timeline
- Start
- 2008-10
- Primary completion
- 2012-08
- Completion
- 2012-08
Outcome
Outcome not reported
Stopped (Enrollment): “Due to poor Accrual”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bevacizumab | Monoclonal antibody | 10 mg/kg | Intravenous |
| Subject | Cetuximab | Monoclonal antibody | 500 mg/m2 | Intravenous |
| Subject | Irinotecan | Small molecule | 110 mg/m2 | Intravenous |
| Subject | Leucovorin | Small molecule | 500 mg/m2 | Intravenous |
| Subject | Oxaliplatin | Small molecule | 85 mg/m2 | Intravenous |
| Subject | fluorouracil | Small molecule | 1750 mg/m2 | Intravenous |